Safety and Efficacy Implications of Discontinuing Combination Ipilimumab and Nivolumab in Advanced Melanoma

Matteo S. Carlino; Shahneen Sandhu

doi:10.1200/jco.2017.75.2055

Related publications

Article2020

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib

Thomas Yau, Yoon‐Koo Kang, Tae‐You Kim, Anthony B. El-Khoueiry, Armando Santoro, Bruno Sangro, Ignacio Melero, Masatoshi Kudo, Ming-Mo Hou, Ana Matilla, Francesco Tovoli, Jennifer J. Knox, Aiwu Ruth He, Bassel F. El‐Rayes, Mirelis Acosta-Rivera, Ho-Yeong Lim, Jaclyn Neely, Yun Shen, Tami Wisniewski, Jeffrey Anderson, Chiun Hsu

Article2020

FDG PET in the evaluation of immune-related hypophysitis and thyroiditis following combination ipilimumab and nivolumab in advanced melanoma

Amir Iravani, Anna Galligan, Arian Lasocki, Roslyn Wallace, Alison M. Weppler, George Au Yeung, Tim Akhurst, Nirupa Sachithanandan, Cherie Chiang, Shahneen Sandhu, Rodney J. Hicks

Article2018

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study

Georgina V. Long, Victoria Atkinson, Serigne Lo, Shahneen Sandhu, Alexander Guminski, Michael P. Brown, James S. Wilmott, Jarem Edwards, Maria Gonzalez, Richard A. Scolyer, Alexander M. Menzies, Grant A. McArthur

Article2020

O-5 Efficacy and safety of nivolumab + ipilimumab in Asian patients with advanced hepatocellular carcinoma: Subanalysis of the CheckMate 040 study

Thomas Yau, Chih‐Hung Hsu, Yoon‐Koo Kang, T. Kim, Ming‐Mo Hou, Ho Yeong Lim, Yee Chao, Y. Kim, Masafumi Ikeda, Su Pin Choo, Jaclyn Neely, Yun Shen, Marina Tschaika, Masatoshi Kudo

Article2020

FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment

Amir Iravani, Medhat Osman, Alison M. Weppler, Roslyn Wallace, Anna Galligan, Arian Lasocki, Morgan Hunter, Tim Akhurst, Michael S. Hofman, Peter K. H. Lau, Damien Kee, George Au‐Yeung, Shahneen Sandhu, Rodney J. Hicks

Safety and Efficacy Implications of Discontinuing Combination Ipilimumab and Nivolumab in Advanced Melanoma

Discussion(0)

Related publications

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib

FDG PET in the evaluation of immune-related hypophysitis and thyroiditis following combination ipilimumab and nivolumab in advanced melanoma

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study

O-5 Efficacy and safety of nivolumab + ipilimumab in Asian patients with advanced hepatocellular carcinoma: Subanalysis of the CheckMate 040 study

FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment